All Comments by Boris Schmidt
Go to another page:
- 1
- 2
- Dyeing Worms for an Extra-Long, Healthy Lifespan?
- Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers.
- Nonspecificity of binding of gamma-secretase modulators to the amyloid precursor protein.
- Modulation of gamma-secretase specificity using small molecule allosteric inhibitors.
- Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels.
- Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
- Chicago: Out of the Blue—A Tau-based Treatment for AD?
- Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.
- EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers.
- Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease.
- Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease.
- Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment.
- Presenilin Loss of Function—Plan B for AD?
- Intra- or intercomplex binding to the gamma-secretase enzyme. A model to differentiate inhibitor classes.
- Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.